Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15924168 | 0.84 | HDAC3 (0.55) | HDAC3HDAC2HDAC1CKS1BSKP1 | |
| SCHEMBL15924171 | 0.80 | CKS1B (0.35) | HDAC3HDAC2HDAC1CKS1BSKP1 | |
| SCHEMBL5228683 | 0.76 | HDAC1 (0.47) | HDAC3HDAC2HDAC1CKS1BSKP1 | |
| SCHEMBL5222720 | 0.75 | HDAC1 (0.48) | HDAC3HDAC2HDAC1 | |
| SCHEMBL15923050 | 0.73 | HDAC3 (0.55) | HDAC3HDAC2HDAC1ALDH1A1LMNA | |
| SCHEMBL15936527 | 0.73 | HDAC3 (0.54) | HDAC3HDAC2HDAC1CKS1BSKP1 | |
| SCHEMBL15683161 | 0.71 | HDAC1 (0.60) | HDAC3HDAC2HDAC1CKS1BSKP1 | |
| SCHEMBL15922958 | 0.71 | HDAC3 (0.57) | HDAC3HDAC2MAPTTSHR | |
| SCHEMBL15922047 | 0.70 | HDAC3 (0.56) | HDAC3MAPTTSHR | |
| SCHEMBL15152261 | 0.69 | HCAR2 (0.39) | CKS1BSKP1SKP2HCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951153-B1 | SELECTIVE HDAC3 INHIBITORS | REGENACY PHARMACEUTICALS LLC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10125131-B2 | Selective HDAC3 inhibitors | REGENACY PHARMACEUTICALS, LLC (US) | 2018-11-13 | — | — | US | disclosed |
| US-20170204094-A1 | Selective HDAC3 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2017-07-20 | — | — | US | disclosed |
| US-9562013-B2 | Selective HDAC3 inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-2951153-A1 | SELECTIVE HDAC3 INHIBITORS | Acetylon Pharmaceuticals, Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150299130-A1 | SELECTIVE HDAC3 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2015-10-22 | — | — | US | disclosed |
| US-9096549-B2 | Selective HDAC3 inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140243345-A1 | SELECTIVE HDAC3 INHIBITORS | REGENACY PHARMACEUTICALS, LLC | 2014-08-28 | — | — | US | disclosed |
| WO-2014121062-A1 | SELECTIVE HDAC3 INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243345-A1 | SELECTIVE HDAC3 INHIBITORS | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC2 4/4885HDAC1 2/4885 |
| US-20150299130-A1 | SELECTIVE HDAC3 INHIBITORS | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC2 4/4885HDAC1 2/4885 |
| US-20170204094-A1 | Selective HDAC3 Inhibitors | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC2 4/4885HDAC1 2/4885 |
| US-10125131-B2 | Selective HDAC3 inhibitors | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC2 4/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.